news

Results from Phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology

Posted: 2 April 2014 | | No comments yet

Data from the first patient preference study in advanced renal cell carcinoma are published in the Journal of Clinical Oncology…

GlaxoSmithKline logo

Data from the first patient preference study in advanced renal cell carcinoma are published today in the Journal of Clinical Oncology1. The study, known as PISCES, showed more patients expressed a preference for continuing treatment with Votrient® (pazopanib) than Sutent® (sunitinib)1. The question asked in the study was “Now that you have completed both treatments, which of the two drugs would you prefer to continue to take as the treatment for your cancer, assuming that both drugs will work equally well in treating your cancer?” Patients selected either first treatment, second treatment or no preference. The objective of PISCES was to investigate patient-reported treatment preference and certain health-related quality of life outcomes for patients with locally advanced and/or metastatic renal cell carcinoma (aRCC or mRCC) who received no prior systemic therapy1.

The results showed that 70% (90%* CI, 60.9-78.4) of patients expressed a preference for pazopanib compared with 22% (90%* CI, 14.7-30.6) expressing preference for sunitinib, as assessed by a questionnaire1. Eight percent of patients expressed no preference1. The PISCES study was not designed to measure or compare the clinical efficacy of either pazopanib or sunitinib1.

One of the secondary endpoints in this study was assessing the reasons for patient preference. The most commonly cited reasons for preferring pazopanib were “better quality of life” and “less fatigue”. In patients preferring sunitinib the most common reasons were “less diarrhoea” and “better quality of life”1 .

Nikki Yates, General Manager of GSK UK commented: “In the current healthcare environment driven by quality and efficiency, GSK recognises the need to demonstrate the benefits of its medicines to patients and PISCES is a great example of this. We hope that the results of this study will provide additional insights from the patients’ perspective into the treatment options available for renal cancer and further inform clinical practice”.

References

  1. Escudier B, Porta C, Bono P, et al. A Randomized, Controlled, Double-blind, Crossover Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients with Metastatic Renal Cell Carcinoma (PISCES Study). J Clin Oncol 2014; 32 (4) Available at: published online at www.jco.org on March 31, 2014; DOI:10.1200/JCO.2013.50.8267

 

Related organisations